Arcutis shares up on news of public, private offerings
Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →
Read More →Amgen to team with Eli Lilly on COVID treatment
Thousand Oaks biotech giant Amgen announced another strategy to help address the coronavirus pandemic, entering into a manufacturing agreement with Eli Lilly to produce COVID-19 antibodies. Eli Lilly, based in Indianapolis, has been pursuing several antibody treatments for the virus, the two companies said in a Sept. 17 news release. With access to Amgen’s manufacturing Read More →
Read More →
Amgen to join exclusive Dow Jones club
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen teams up with competitors in COVID treatment trial
Amgen has joined two of its competitors in launching a trial for drugs to treat patients with COVID-19. Together with Chicago-based AbbVie and Japanese drugmaker Takeda Pharmaceutical, the Thousand Oaks biotech giant said Aug. 3 it had enrolled the first patients into a clinical trial for the anti-inflammatory drugs Otezla, cenicriviroc and Firazyr. Otezla is Read More →
Read More →Amgen meets analyst estimates, but shares drop on Q2 earnings decline
Amgen’s revenues climbed 6 percent in the second quarter, to $6.2 billion, despite the COVID-19 pandemic limiting hospital and physician operations and putting a hitch in diagnosis and treatment for many patients. Amgen’s earnings, announced July 28, met average analyst estimates. However, a 17 percent overall decline in net income for the Thousand Oaks biotech Read More →
Read More →Amgen puts $421M into BeiGene
Thousand Oaks biotech giant Amgen has upped its investment in Chinese oncology research firm BeiGene by $421 million. Amgen’s new investment, announced July 13, will allow the company maintain its ownership interest in BeiGene at 20.3 percent following a direct offering by the Chinese firm. Amgen shares rose more than 1 percent following the news Read More →
Read More →Amgen’s growth over 40 years key to tri-county economy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
